Medtronic (MDT) gains after boosting full-year guidance

Go back to Medtronic (MDT) gains after boosting full-year guidance

Medtronic (MDT) Tops Q3 EPS by 4c; raises FY24 Guidance

February 20, 2024 7:03 AM EST

Medtronic (NYSE: MDT) reported Q3 EPS of $1.30, $0.04 better than the analyst estimate of $1.26. Revenue for the quarter came in at $8.1 billion versus the consensus estimate of $7.95 billion.

GUIDANCE:

Medtronic sees FY2024 EPS of $5.19-$5.21, versus the consensus of $5.16.

The... More

Medtronic (MDT) to Exit Ventilator Product Line, Reports Q3, Issues Guidance

February 20, 2024 6:47 AM EST

Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024.

Patient Monitoring and Respiratory Interventions (PMRI) Update
Medtronic has decided to exit its ventilator product line and retain and combine the remaining PMRI businesses into one business unit called Acute Care and Monitoring (ACM). Exiting the increasingly unprofitable ventilator product line and combining the remaining businesses allows for increased investment in ACM with a focus on profitable growth. Given this increased investment... More

Medtronic (MDT) call put ratio 4.2 calls to 1 put into quarter results

February 16, 2024 10:42 AM EST

Medtronic (NYSE: MDT) February weekly call option implied volatility is at 33, March is at 34; compared to its 52-week range of 15 to 29 into the expected release of quarter results before the bell on February 20.

... More

Medtronic (MDT) February weekly 85 straddle into quarter results

February 16, 2024 4:58 AM EST

Medtronic (NYSE: MDT) February weekly 85 straddle priced for a move of 5% into the expected release of quarter results before the bell on February 20.

... More